Insilico Nominates AI-Designed ISM9077, Potential First-in-Class Y Inhibitor, as Preclinical Candidate
Insilico Medicine has nominated ISM9077, an artificial intelligence-designed inhibitor of an undisclosed “Target Y,” as a preclinical candidate for dry...
